How should we treat hypertensive women with cardiac and renal impairment?

American Journal of Hypertension

Volumn 10, Issue 10 II SUPPL., 1997, Pages

  Ruilope, Luis M ^a   Suarez, Carmen ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Cardiovascular risk; Essential hypertension; Left ventricular hypertrophy; Microalbuminuria; Nephrosclerosis

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ARTICLE; CARDIOVASCULAR RISK; DRUG EFFECT; HEART DISEASE; HUMAN; HYPERTENSION; KIDNEY DISEASE; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 0030727721     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(97)00330-0     Document Type: Article

References (46)

1. Fiebach NH, Hebert PR, Stampfer MJ, et al. A prospective study of high blood pressure and cardiovascular disease in women. Am J Epidemiol. 130:1989;646-654.
2. Kaplan NM. The treatment of hypertension in women. Arch Intern Med. 155:1995;563-567.
3. Anastos K, Charney P, Charon RA, et al. Hypertension in women what is really known? Ann Intern Med. 115:1991;287-293.
4. Bittner V. Hypertension in women. Curr Opin Nephrol Hypertens. 4:1995;204-207.
5. Isles C. Blood pressure in males and females. J Hypertens. 13:1995;285-290.
6. Isles CG, Hole DJ, Hawthorne VM, Lever AF. Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey comparison with men . Lancet. 339:1992;702-706.
7. MRC trial of treatment of mild hypertension. Br Med J. 291:1985;97-104.
8. Sever P, Beevers G, Bulpitt C, et al. Management guidelines in essential hypertension report of the second working party of the British Hypertension Society . Br Med J. 306:1993;983-987.
9. Jackson R, Barham P, Bills J, et al. Management of raised blood pressure in New Zealand a discussion document . Br Med J. 307:1993;107-110.
10. Castelli WP. Cardiovascular disease in women. Am J Obstet Gynaecol. 158:1988;1553-1560.
11. Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet. 338:1991;1281-1285.
12. Medical Research Council trial of treatment of hypertension in older adults principal results . Br Med J. 328:1993;914-921.
13. Kannel WB, Wilson PW. Risk factors that attenuate the female coronary disease advantage. Arch Intern Med. 155:1995;57-61.
14. Casale PN, Devereux RB, Milner M, et al. Value of echocardiographic measurement of left ventricular hypertrophy among employed patients with uncomplicated hypertension. Ann Intern Med. 105:1986;173-178.
15. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 114:1991;345-352.
16. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 322:1990;1561-1566.
17. Chambers J. Left ventricular hypertrophy An underappreciated coronary risk factor . Br Med J. 311:1995;273-274.
18. Perera GA. Hypertensive vascular disease description and natural history . J Chronic Dis. 1:1955;33-42.
19. Ruilope LM, Campo C, Rodriguez-Artalejo F, et al. Blood pressure and renal function therapeutic implications . J Hypertens. 14:1996;1259-1263.
20. Shulman NB, Ford CE, Hall WD, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function Results from the Hypertension Detection and Follow-up Program . Hypertension. 13(suppl I):1989;1-80-1-93.
21. Aronow WS. Usefulness of serum creatinine as a marker for coronary events in elderly patients with either systemic hypertension or diabetes mellitus. Am J Cardiol. 68:1991;678-679.
22. Samuelsson O. Hypertension in middle-aged man management, morbidity and prognostic factors during long-term hypertensive care . Acta Med Scand. 702(suppl):1985;1-79.
23. Agrawal B, Berger A, Wolf K, Luft FC. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens. 14:1996;223-228.
24. Ljungman S, Wikstrand J, Hartford M, Berglund G. Urinary albumin excretion - a predictor or risk of cardiovascular disease a prospective 10-year follow-up of middle-aged normal and hypertensive men . Am J Hypertens. 8:1996;770-778.
25. Gorgels WJ, Van der Graaf Y, Hjendahl R, et al. Urinary excretions of high molecular weight beta-thromboglobulin and albumin are independently associated with coronary heart disease in women - a nested case-control study of middle-aged women in the Diagnostich Onderzoek Mammacarcinoom (DOM) cohort, Utrecht, The Netherlands. Am J Epidemiol. 192:1995;1157-1164.
26. Rostand SG, Brunzell JD, Cannon RO, Victor RG. Cardiovascular complications in renal failure. J Am Soc Nephrol. 2:1991;1053-1058.
27. Takazakura E, Sawabu N, Handa A, et al. Intrarenal vascular changes with age and disease. Kidney Int. 2:1972;224-230.
28. Tracy RE, Bhandaru SY, Oalmann MC, et al. Blood pressure and nephrosclerosis in black and white men and women aged 25 to 54. Mod Pathol. 4:1991;602-609.
29. Tracy RE, Malcom GT, Oalmann MC, et al. Nephrosclerosis in coronary heart disease. Mod Pathol. 7:1994;301-309.
30. Tracy RE, Strong JP, Newman WP III, et al. Renovasculopathies of nephrosclerosis in relation to atherosclerosis at ages 25-54 years. Kidney Int. 49:1996;564-570.
31. Ruilope LM, Rodicio JL. Microalbuminuria in clinical practice. Kidney A Current Survey of World Literature . 4:1995;211-216.
32. Cerasola G, Cottone S, Mule G, et al. Microalbuminuria, renal dysfunction and cardiovascular complications in essential hypertension. J Hypertens. 14:1996;915-920.
33. Redon J, Gomez-Sanchez MA, Baldo E, et al. Microalbuminuria is correlated with left ventricular hypertrophy in male hypertensive patients. J Hypertens. 9(suppl 6):1991;S148-S149.
34. Bigazzi R, Bianchi G, Nanci R, et al. Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuria. J Hum Hypertens. 9:1995;827-833.
35. Roman MJ, Pickering TG, Schwartz JE, et al. Association of carotid atherosclerosis and left ventricular hypertrophy. J Am Coll Cardiol. 125:1995;83-90.
36. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, Part 2 Short-term reductions in blood pressure: overview of randomised drug trials in the epidemiological context . Lancet. 335:1990;827-838.
37. Sytkowski PA, D'Agostino RB, Belanger AJ, Kannel WB. Secular trends in long-term sustained hypertension, long-term treatment and cardiovascular mortality. Circulation. 93:1996;697-703.
38. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients a metaanalysis of 109 treatment studies . Am J Hypertens. 5:1992;95-110.
39. Schmieder RE, Martus P, Klingbell A. Reversal of left ventricular hypertrophy in essential hypertension A meta-analysis of randomized double-blind studies . JAMA. 275:1996;1507-1513.
40. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 90:1994;2056-2069.
41. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 329:1993;1456-1462.
42. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 334:1996;939-945.
43. Ruilope LM, Alcazar JM, Hernandez E, et al. Long-term influences of antihypertensive therapy on microalbuminuria in essential hypertension. Kidney Int. 45(suppl 45):1994;S171-S173.
44. Himmelmann A, Hansson L, Hansson BG, et al. ACE inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension. Blood Pressure. 4:1995;85-90.
45. Schiffrin EL, Deng LY. Comparison of the effects of angiotensin I-converting enzyme inhibition and beta-blockade for 2 years on function of small arteries from hypertensive patients. Hypertension. 25(part 2):1995;699-703.
46. Sihn I, Shroeder AP, Aalkjaer C, et al. Regression of media-to-lumen ratio of human subcutaneous arteries and left ventricular hypertrophy during treatment with an angiotensin-converting enzyme inhibitor based regimen in hypertensive patients. Am J Cardiol. 76:1995;38E-40E.